Gurpreet Kaur Sagoo: A Rare Bone Marrow Failure Syndrome That Challenges Early Diagnosis
Gurpreet Kaur Sagoo, Professor at Armed Forces Medical College, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Medical Journal of Dr. D.Y. Patil Vidyapeeth, adding:
”Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare autosomal‑recessive bone‑marrow‑failure syndrome that can mimic several other neonatal and infantile thrombocytopenic disorders, leading to diagnostic dilemmas. The key is to suspect CAMT early in infants with persistent or progressive thrombocytopenia, even when presentation is atypical or delayed
Core diagnostic features of CAMT
- Thrombocytopenia at or shortly after birth, often severe (<50K/cumm )with normal‑sized platelets and no dysmorphic features.
- Bone‑marrow examination shows absent or markedly reduced megakaryocytes; red and white lineages are usually normal initially but may progress to pancytopenia.
- Serum thrombopoietin (TPO) levels are very high due to loss of c‑MPL receptor‑mediated clearance, and genetic testing confirms homozygous or compound heterozygous MPL mutations.
Common diagnostic dilemmas
1. Differentiating from acquired thrombocytopenias Neonatal thrombocytopenia is more often acquired (e.g., infection, immune, disseminated intravascular coagulation) than congenital.
Dilemmas arise when:
- Thrombocytopenia is detected only after the newborn period, because CAMT can present beyond the first days of life.
- No family history or obvious consanguinity is present, so clinicians lean toward transient or immune causes. Points to consider:
- Persistent thrombocytopenia despite resolution of infection or sepsis warrants bone‑marrow evaluation and TPO testing.
- Normal platelet size and normal early red/white cell counts favor CAMT over some immune or consumptive causes.”
Title: Congenital Amegakaryocytic Thrombocytopenia – An Unusual Cause of Bleeding Diasthesis in a Toddler
Authors: Lalit Khawse, Gurpreet Kaur, Ankur Ahuja, Venkatesan Samasundaram

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy